Mesoblast Limited - American Depositary Shares — 현금 흐름 (NASDAQ:MESO)

Financials

영업활동으로 인한 현금 106.68 M65.78 M63.27 M48.46 M49.95 M — 투자 활동으로 인한 현금 1.65 M232 K194 K97 K120 K — 재무활동으로 인한 현금 114.47 M9.87 M74.5 M40.25 M147.34 M — 잉여 현금 흐름 106.68 M65.78 M63.27 M48.46 M49.95 M —

Mesoblast Limited - American Depositary Shares

Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.

MESO

Financials

Mesoblast Limited - American Depositary Shares

뉴스

Mesoblast Limited: A Risk/Reward Story (NASDAQ:MESO)

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript

Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade) (NASDAQ:MESO)

Mesoblast H1 FY26 slides: first approved MSC product hits $49M

Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication - Mesoblast (NASDAQ:MESO)

FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain - Mesoblast (NASDAQ:MESO)

Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session - American Express (NYSE:AXP), Bread Finl Hldgs (NYSE:BFH)

Mesoblast, 52주 신고가 경신, 21.05 USD 기록

Mesoblast stock reaches 52-week high at 21.05 USD

Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales - Mesoblast (NASDAQ:MESO)

메소블라스트, 이사회 리더십 교체 발표

Mesoblast announces board leadership changes as company evolves